Generics Bulletin l Pharma Intelligence

How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.

How it works
A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.

Analysis and opinion covers key topic areas such as:

Regulatory and compliance changes
Legal and legislations advances
Competitive developments
Merger and acquisition activities
New product launches
Marketing challenges
Advertising strategies, and more.

Start a free trial

Generics Bulletin

Indian Leaders Begin Unique Collaboration On Molnupiravir

Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.

Generics Bulletin

Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

Generics Bulletin

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Generics Bulletin

New COVID-19 Vaccine Patent Database Launched

As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.

Generics Bulletin

Celltrion Opens Up Canadian Market For Remsima SC

GB2106_Canada_Open_Door_Flag_DYRCJR_1200

Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

Generics Bulletin

Industry Steps Up To Help India Through Second Wave

As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus.

Generics Bulletin

European Biosimilars Can Benefit From Sharing Experiences

GB2104_Europe_Connections_Map_Space_2A9CJEX_1200

Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

Generics Bulletin

FDA Guides On Generic Development During COVID-19

Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.

Generics Bulletin

Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

Generics Bulletin

FDA Guides On Bioequivalence Studies And COVID-19

USFDAentrancesignwithblueskybehindit_1200

Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.

Generics Bulletin

EU Reforms Must Heed Pandemic Lessons

Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

Generics Bulletin

Glenmark Debuts Favipiravir For COVID-19 In India

Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

Generics Bulletin

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Generics Bulletin

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Generics Bulletin

European Industry Played Key Role In Mitigating COVID-19

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

Generics Bulletin

In-depth news and analysis

What's included

Below are the Feature List

Ask-the-Analyst™ Service

A powerful online platform

In-depth content coverage

Global analysts and journalists

Pharma Intelligence: latest

Latest headlines

Meet the team

Below are the Analyst Profile

Aidan Fry

Editor, Executive Editor, Commercial/R&D

Duncan Emerton

Consultant, Executive Director, Custom Intelligence & Analytics

Andrea Charles

Editor, Editor, Custom Content

Related Products

Biomedtracker: see the drug development process through analysts’ eyes

Pink Sheet: global policy and regulatory coverage

HBW Insight: Health, Beauty and Wellness

Next steps

This is Contactus Section

Request a Trial

How can we help you?

Pharma Report Store